Mon. Jul 4th, 2022
Tatva Chintan Pharma Chem IPO opens today: Should you subscribe? On account of strong growth potential, dominant manufacturer status, potential play on #39;green chemistry#39; and discounted valuation compared to its peers, KR Choksey recommended a #39;subscribe#39; rating for long term gains for Tatva Chintan IPO.